# Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases

> **NCT00910039** · PHASE2 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Cognitive/Functional Effects
- Metastatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** sunitinib malate
- **OTHER:** cognitive assessment

## Key facts

- **NCT ID:** NCT00910039
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2012-01
- **Final completion:** 2014-04
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2014-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00910039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00910039, "Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00910039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*